Lilly Faces Sales Setback Amid Disappointing Weight Loss Drug Performance

Pharmaceutical giant Eli Lilly has reported a decline in its sales figures for the third quarter of 2024, primarily attributed to the underperformance of its weight-loss drug, a critical component of its recent growth strategy. Despite the company’s robust portfolio, the latest earnings report fell short of analysts' anticipations, leading to concerns about future growth and profitability.

Continue reading